Lawrence D True

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc Methodological requirements for valid tissue-based biomarker studies that can be used in clinical practice
    Lawrence D True
    Department of Pathology, University of Washington Medical Center, 1959 NE Pacific St, Box 356100, Seattle, WA, USA
    Virchows Arch 464:257-63. 2014
  2. pmc Quantum dots for molecular pathology: their time has arrived
    Lawrence D True
    Department of Pathology, University of Washington Medical Center, Room BB220, 1959 NE Pacific St, Box 356100, Seattle, WA 98195 6100, USA
    J Mol Diagn 9:7-11. 2007
  3. pmc Quality control in molecular immunohistochemistry
    Lawrence D True
    Department of Pathology, University of Washington, 1959 NE Pacific St, Box 35 6100, Seattle, WA, USA
    Histochem Cell Biol 130:473-80. 2008
  4. pmc The accumulation of versican in the nodules of benign prostatic hyperplasia
    Lawrence D True
    Department of Pathology, University of Washington, Seattle, Washington 98195 6100, USA
    Prostate 69:149-58. 2009
  5. pmc Immunohistochemical validation of expression microarray results
    Lawrence True
    Department of Pathology, Room EE110, 1959 NE Pacific St, Box 356100, University of Washington, Seattle, WA 98195, USA
    J Mol Diagn 7:149-51. 2005
  6. pmc A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49
    Lawrence D True
    Department of Pathology, University of Washington, Seattle, Washington, USA
    Am J Pathol 161:705-15. 2002
  7. ncbi request reprint The cancer nuclear microenvironment: interface between light microscopic cytology and molecular phenotype
    Lawrence D True
    Department of Pathology, University of Washington, Seattle, Washington 98119, USA
    J Cell Biochem 104:1994-2003. 2008
  8. pmc Prostate cancer cell phenotypes based on AGR2 and CD10 expression
    Melissa E Ho
    Department of Urology, University of Washington, Seattle, WA 98195 6100, USA
    Mod Pathol 26:849-59. 2013
  9. pmc Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate
    Laura E Pascal
    Department of Urology, University of Washington, Seattle WA 98195, USA
    BMC Genomics 9:246. 2008
  10. pmc The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Prostate 70:412-24. 2010

Detail Information

Publications84

  1. pmc Methodological requirements for valid tissue-based biomarker studies that can be used in clinical practice
    Lawrence D True
    Department of Pathology, University of Washington Medical Center, 1959 NE Pacific St, Box 356100, Seattle, WA, USA
    Virchows Arch 464:257-63. 2014
    ..Strategic goals are formulated in order to improve on the quality of biomarker reporting, including issues of analyte quality, experimental detail, assay efficiency and precision, and assay appropriateness. ..
  2. pmc Quantum dots for molecular pathology: their time has arrived
    Lawrence D True
    Department of Pathology, University of Washington Medical Center, Room BB220, 1959 NE Pacific St, Box 356100, Seattle, WA 98195 6100, USA
    J Mol Diagn 9:7-11. 2007
    ..Quantum dot-conjugated probes to specific biomarkers are powerful tools that can be applied in a multiplex manner to single tissue sections of biopsies to measure expression levels of multiple biomarkers...
  3. pmc Quality control in molecular immunohistochemistry
    Lawrence D True
    Department of Pathology, University of Washington, 1959 NE Pacific St, Box 35 6100, Seattle, WA, USA
    Histochem Cell Biol 130:473-80. 2008
    ....
  4. pmc The accumulation of versican in the nodules of benign prostatic hyperplasia
    Lawrence D True
    Department of Pathology, University of Washington, Seattle, Washington 98195 6100, USA
    Prostate 69:149-58. 2009
    ..Versican expression is elevated in tissues with increased proliferation. Based on these observations, we determined the extent and distribution of versican expression in prostates with BPH...
  5. pmc Immunohistochemical validation of expression microarray results
    Lawrence True
    Department of Pathology, Room EE110, 1959 NE Pacific St, Box 356100, University of Washington, Seattle, WA 98195, USA
    J Mol Diagn 7:149-51. 2005
  6. pmc A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49
    Lawrence D True
    Department of Pathology, University of Washington, Seattle, Washington, USA
    Am J Pathol 161:705-15. 2002
    ..This xenograft should prove to be useful in the investigation of mechanisms underlying the androgen-insensitive state of progressive prostate carcinoma...
  7. ncbi request reprint The cancer nuclear microenvironment: interface between light microscopic cytology and molecular phenotype
    Lawrence D True
    Department of Pathology, University of Washington, Seattle, Washington 98119, USA
    J Cell Biochem 104:1994-2003. 2008
    ..This article delves into the basis of nuclear structure at different levels of resolution--light microscopic, electron microscopic, and molecular...
  8. pmc Prostate cancer cell phenotypes based on AGR2 and CD10 expression
    Melissa E Ho
    Department of Urology, University of Washington, Seattle, WA 98195 6100, USA
    Mod Pathol 26:849-59. 2013
    ..It appears that AGR2 has a protective function in primary tumors but may have a role in the distal spread of tumor cells...
  9. pmc Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate
    Laura E Pascal
    Department of Urology, University of Washington, Seattle WA 98195, USA
    BMC Genomics 9:246. 2008
    ..Immunohistochemical stains of prostate tissues from more than 50 patients were scored for informative CD antigen expression and compared with cell-type specific transcriptomes...
  10. pmc The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Prostate 70:412-24. 2010
    ..Tumor cells replace bone marrow and can elicit an osteoblastic, osteolytic, or mixed bone response. Our objective was to elucidate the mechanisms and key factors involved in promoting osteoclastogenesis in PCa bone metastasis...
  11. ncbi request reprint Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer
    Elahe A Mostaghel
    Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA
    Cancer Res 67:5033-41. 2007
    ..Optimal clinical efficacy will require testing of novel approaches targeting complete suppression of systemic and intracrine contributions to the prostatic androgen microenvironment...
  12. pmc Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    J Bone Miner Res 28:333-40. 2013
    ..Furthermore, in this cohort of patients, BP treatment increased BV and did not decrease the number of osteoclasts in prostate cancer bone metastases compared with bone metastases from patients who did not receive BP...
  13. pmc Androgen receptor variants occur frequently in castration resistant prostate cancer metastases
    Xiaotun Zhang
    Department of Urology, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e27970. 2011
    ..Since specific antibodies detecting all C-terminal truncated AR variants are not available, our aim was to develop an approach to assess the prevalence and function of AR variants in prostate cancer (PCa)...
  14. pmc Gene expression down-regulation in CD90+ prostate tumor-associated stromal cells involves potential organ-specific genes
    Laura E Pascal
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    BMC Cancer 9:317. 2009
    ..The tumor-associated stroma is marked by increased expression of CD90/THY1. Isolation and characterization of these stromal cells could provide valuable insight into the biology of the tumor microenvironment...
  15. pmc Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases
    Sandy R Larson
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Prostate 73:932-40. 2013
    ..We determined whether previously identified and/or novel proteins were associated with the osteoblastic or osteolytic response in clinical specimens of PCa bone metastases...
  16. pmc Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes
    Laura E Pascal
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    BMC Cancer 9:452. 2009
    ..This CD phenotype suggests a lineage relationship between cancer cells and luminal cells. The Gleason grade of tumors is a descriptive of tumor glandular differentiation. Higher Gleason scores are associated with treatment failure...
  17. pmc Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth
    R Bruce Montgomery
    Department of Medicine, University of Washington School of Medicine, Weattle, WA, USA
    Cancer Res 68:4447-54. 2008
    ..Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment...
  18. pmc Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    Prostate 70:1799-808. 2010
    ..Therefore, we hypothesized that the inhibition of angiopoietin-2 activity in PCa will impede angiogenesis, tumor growth, and alter bone response in vivo...
  19. pmc Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect
    Michael C Risk
    Departments of Urology and Pathology, University of Washington Medical Center, 1959 NW Pacific Street, Seattle, WA 98195, USA
    Clin Cancer Res 16:5414-23. 2010
    ..We sought to determine if histologically benign prostate epithelium collected from men with prostate cancer exhibits features indicative of premalignancy or field effect...
  20. pmc Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression
    Asa J Oudes
    Institute for Systems Biology, Seattle, USA
    BMC Cancer 5:86. 2005
    ..In this study, two lineage-related prostate cancer cell lines, LNCaP and C4-2, were used for transcriptome analysis with the aim of identifying genes associated with prostate cancer progression...
  21. pmc Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention
    Elahe A Mostaghel
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D4 100, Seattle, WA 91809, USA
    Cancer Res 70:1286-95. 2010
    ..Our findings suggest that AR levels may predict the chemopreventive efficacy of SRD5A inhibitors...
  22. ncbi request reprint LuCaP 35: a new model of prostate cancer progression to androgen independence
    Eva Corey
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Prostate 55:239-46. 2003
    ..Generation of suitable in vivo models is critical for understanding of processes associated with development and progression of prostate cancer (CaP)...
  23. ncbi request reprint Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases
    Colm Morrissey
    Genitourinary Cancer Research Laboratory, Department of Urology, University of Washington, Seattle, WA 98195, USA
    Clin Exp Metastasis 25:377-88. 2008
    ..In addition, the resulting tumor-associated microvessel density and distribution was significantly different between liver and bone metastasis possibly in response to the protein expression changes detailed above...
  24. pmc Transcriptomes of human prostate cells
    Asa J Oudes
    Urology, University of Washington, Seattle, WA 98195 6510, USA
    BMC Genomics 7:92. 2006
    ..To overcome the problem of heterogeneity we have developed a method to isolate individual cell types from whole tissue that are a source of RNA suitable for transcriptome profiling...
  25. pmc Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer
    Ilona N Holcomb
    Divisions of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA
    Cancer Res 69:7793-802. 2009
    ..Our investigation lays the foundation for a better understanding of and possible therapeutic targets for CR disease, the poorly responsive and final stage of prostate cancer...
  26. ncbi request reprint Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma
    Stacy Moore
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Int J Cancer 114:563-71. 2005
    ..These results indicate that loss of SCD expression is a frequent event in prostate adenocarcinoma, and further supports a role for altered lipid metabolism as a factor in the process of carcinogenesis...
  27. ncbi request reprint Metastases of prostate cancer express estrogen receptor-beta
    Janice S Lai
    Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Urology 64:814-20. 2004
    ..It has been proposed that ERbeta may play a role in the growth regulation of prostate cells. The targeting of ERs by selective ER modulators might be an effective method of treating advanced CaP...
  28. pmc Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases
    Canan Akfirat
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Pathol 230:291-7. 2013
    ..Altogether, this suggests that optimal therapeutic inhibition may require combinations of drugs that target both bone and soft tissue-specific survival pathways...
  29. ncbi request reprint Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE)
    Eric W Deutsch
    Institute for Systems Biology, 1441 N 34th Street, Seattle, Washington 98103, USA
    Nat Biotechnol 26:305-12. 2008
    ..This specification has benefited the consortium within which it was developed and is expected to benefit the wider research community. We welcome feedback from the scientific community to help improve our proposal...
  30. pmc Histopathological assessment of prostate cancer bone osteoblastic metastases
    Martine P Roudier
    Department of Pathology, University of Washington and Research Service, Seattle, Washington, USA
    J Urol 180:1154-60. 2008
    ..The discrepancy between the radiological and clinical aspects of those events is not well understood. We better characterized the histopathology of bone processes in prostate cancer bone metastases...
  31. ncbi request reprint Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15
    Chung Ying Huang
    Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98105 1024, USA
    Clin Cancer Res 13:5825-33. 2007
    ..To identify molecular alterations associating with in vivo exposure of prostate carcinoma to chemotherapy and assess functional roles modulating tumor response and resistance...
  32. ncbi request reprint Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence
    Jason P Izard
    Departments of Urology Pathology, University of Washington, Seattle, WA
    Am J Surg Pathol 38:333-8. 2014
    ..48-2.99). Cancer that is within 0.1 mm of the surgical margin of a prostatectomy is associated with an increased risk for PCa recurrence. Patients with that margin status may be reasonable candidates for adjuvant local therapy...
  33. pmc Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes
    Alvin Y Liu
    Department of Urology and Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98195, USA
    Cell Tissue Res 348:589-600. 2012
    ..These cell-type transcriptomes provide a means to monitor in vitro models in which various CD-isolated cell types can be combined to study bladder differentiation and bladder tumor development based on cell-cell interaction...
  34. pmc Molecular and cellular characterization of ABCG2 in the prostate
    Laura E Pascal
    Department of Urology, and the Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98195, USA
    BMC Urol 7:6. 2007
    ..This phenotype is mainly mediated by the ATP-binding cassette membrane transporter ABCG2...
  35. pmc Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients
    Ilona N Holcomb
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Cancer Res 68:5599-608. 2008
    ..Our analysis lays the foundation for elucidation of the relationship between DTC genomic alterations and progressive prostate cancer...
  36. ncbi request reprint Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone
    Martine P Roudier
    Department of Urology, University of Washington, and Puget Sound VA Medical Center, Seattle, 98195, USA
    Hum Pathol 34:646-53. 2003
    ..Consequently, therapy directed to the phenotype of 1 metastasis may have no effect on other metastases in the same patient because of phenotypic heterogeneity...
  37. pmc Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis
    Xiaotun Zhang
    Department of Urology, University of Washington, Seattle, Washington, USA
    Prostate 69:727-36. 2009
    ..However, the nature of PAR expression in prostate tumor microenvironment is not fully understood. We therefore evaluated PAR-1 and PAR-2 expression in primary prostate cancer and bone metastasis...
  38. pmc Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile
    Alvin Y Liu
    Department of Urology, Box 356510, University of Washington, Seattle, WA 98195, USA
    Am J Pathol 165:1543-56. 2004
    ....
  39. pmc Differential expression of CD10 in prostate cancer and its clinical implication
    Marc A Dall'Era
    Department of Urology, University of Washington, Seattle, WA, USA
    BMC Urol 7:3. 2007
    ..We hypothesize that prostate tumors expressing high levels of CD10 have a more aggressive biology with an early propensity towards lymph node metastasis...
  40. pmc A causal role for ERG in neoplastic transformation of prostate epithelium
    Olga Klezovitch
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 105:2105-10. 2008
    ..Our data demonstrate that ERG plays an important causal role in the transformation of prostate epithelium and should be considered as a target for prevention or early therapeutic intervention...
  41. ncbi request reprint The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd-103 brachytherapy
    Hiroki Mitsuyama
    Department of Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA 98108 1597, USA
    Am J Clin Oncol 30:597-600. 2007
    ..To determine the effect of high-grade prostate cancer (Gleason pattern 5) on the prognosis of patients treated with Pd-103 brachytherapy...
  42. ncbi request reprint Molecular characterization of prostatic small-cell neuroendocrine carcinoma
    Nigel Clegg
    Division of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington Seattle, 1100 Fairview Avenue North, Seattle, WA 98109 1024, USA
    Prostate 55:55-64. 2003
    ..In this report, we sought to characterize the gene expression profile of a prostate small cell NE carcinoma by assessing the diversity and abundance of transcripts in the LuCaP 49 prostate small cell carcinoma xenograft...
  43. pmc CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker
    Lawrence D True
    Department of Pathology, University of Washington, Seattle, WA 98195 6100, USA
    Mod Pathol 23:1346-56. 2010
    ....
  44. ncbi request reprint Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia
    Zejing Wang
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    Int J Cancer 105:123-9. 2003
    ..Our results demonstrated that human CaP cells express HCAP and the expression of HCAP is associated with the progression of CaP and the development of CaP cachexia...
  45. pmc Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate
    Beatrice S Knudsen
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Am J Pathol 167:255-66. 2005
    ..24). These results suggest that HAI-1 regulates the HGF Met axis on prostate epithelial cells and influences HGF mediated tumor invasion and metastasis...
  46. doi request reprint Protease-activated receptor 2 signaling upregulates angiogenic growth factors in renal cell carcinoma
    Xiaotun Zhang
    Department of Urology, University of Washington, Seattle, Washington 98195, United States
    Exp Mol Pathol 94:91-7. 2013
    ..To our knowledge, this is the first report that characterized PAR-2 expression in RCC tissue and further demonstrated that PAR-2 has a critical role in regulating angiogenesis in RCC...
  47. pmc The urologic epithelial stem cell database (UESC) - a web tool for cell type-specific gene expression and immunohistochemistry images of the prostate and bladder
    Laura E Pascal
    Department of Urology, and the Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle WA 98195, USA
    BMC Urol 7:19. 2007
    ..Similarly, such information is available for urinary bladder cell types...
  48. doi request reprint The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study
    Jesse K McKenney
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    J Urol 186:465-9. 2011
    ..We evaluated the reproducibility of Gleason grading as relevant to the clinical treatment of men on active surveillance...
  49. ncbi request reprint Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer
    Peter C Black
    Department of Urology, University of Washington, Seattle, Washington, USA
    Prostate 67:743-56. 2007
    ..Although protease-activated receptors (PARs) have been described to play a role in different malignancies, their expression and biological activity in prostate cancer are mostly unknown...
  50. pmc Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality
    Jonathan L Wright
    Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA
    J Urol 183:2213-8. 2010
    ..Using a large, population based national cancer registry we evaluated the risk of prostate cancer specific mortality associated with margin status...
  51. ncbi request reprint Analyzing patterns of staining in immunohistochemical studies: application to a study of prostate cancer recurrence
    Ruth Etzioni
    Translational and Outcomes Research, Fred Hutchinson Cancer Research Center, Mailstop M2 B230, 1100 Fairview Avenue North, P O Box 19024, Seattle, WA 98109, USA
    Cancer Epidemiol Biomarkers Prev 14:1040-6. 2005
    ..In this article, we introduce analytic approaches that explicitly consider both the frequency and intensity of tissue staining...
  52. ncbi request reprint Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases
    Martine P Roudier
    Department of Urology, University of Washington Medical Center, Seattle, WA 98195, USA
    Cancer Treat Res 118:311-39. 2004
  53. ncbi request reprint Persistent intraprostatic androgen concentrations after medical castration in healthy men
    Stephanie T Page
    University of Washington Medical Center, Division of Metabolism, Endocrinology and Nutrition, Box 357138, 1959 NE Pacific, Seattle, WA 98195
    J Clin Endocrinol Metab 91:3850-6. 2006
    ..Studies of men with prostate cancer have suggested that prostatic androgens are preserved in the setting of castration. Tissue androgens might stimulate prostate growth, producing adverse clinical consequences...
  54. ncbi request reprint Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma
    Rizwan Nurani
    Department of Radiation Oncology, Puget Sound Health Care System, Seattle, Washington 98108 1597, USA
    J Urol 178:1968-73; discussion 1973. 2007
    ....
  55. doi request reprint Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence
    Hong Gee Sim
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    J Urol 179:1775-9. 2008
    ..We studied the pathological and biochemical outcome following radical prostatectomy in men with Gleason sum 7 and tertiary Gleason pattern 5...
  56. ncbi request reprint The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd 103 plus beam radiation therapy
    Tracy Sherertz
    Department of Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, Washington 98108, USA
    Cancer J 10:301-6. 2004
    ..Accordingly, we have analyzed the effect of pattern 5 cancer on the prognosis of prostate cancer treated with Pd-103 brachytherapy...
  57. doi request reprint Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine
    Elizabeth A Wayner
    Antibody Resource, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Prostate 72:1023-34. 2012
    ..Overexpression in primary tumors was verified by tissue microarray analysis. AGR2 encodes a 19-kDa secreted protein that might be found in urine...
  58. pmc Stromal mesenchyme cell genes of the human prostate and bladder
    Young Ah Goo
    Department of Urology, University of Washington, Seattle, WA, USA
    BMC Urol 5:17. 2005
    ..We propose to identify the prostate stromal genes by analysis of differentially expressed genes between prostate and bladder stromal cells, and to examine their expression in prostate cancer...
  59. pmc Fibroblast growth factor-10 signals development of von Brunn's nests in the exstrophic bladder
    Rocky Eastman
    Program in Human Urothelial Biology, Center for Tissue and Cell Sciences, Seattle Children s Research Institute, 1900 9th Ave, Mailstop C9S 5, Seattle, WA 98101, USA
    Am J Physiol Renal Physiol 299:F1094-110. 2010
    ..The collective evidence points to a mechanism where von Brunn's nests develop under the control of the FGF-10 signal transduction system and suggests that 10pRp cells may be the original source of nested cells...
  60. ncbi request reprint WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence
    Biaoyang Lin
    Zhejiang California International Nanosystems Institute, Hangzhou, China
    Clin Cancer Res 14:1397-406. 2008
    ..We previously identified WDR19 as a prostate-specific, androgen-regulated gene. Here, we evaluate its utility as a prostate cancer tissue marker for diagnosis and prognostic evaluation...
  61. ncbi request reprint Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy
    Jacques Corriveau
    Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA, USA
    Brachytherapy 2:108-13. 2003
    ..To determine if gap time variations between prostate brachytherapy and supplemental beam radiation (EBRT) affect postimplant morbidity...
  62. ncbi request reprint The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cure
    Nathan Bittner
    Department of Radiation Oncology, University of Washington, Seattle, WA 98195 6043, USA
    Am J Clin Oncol 31:231-6. 2008
    ..To determine whether treatment gap between supplemental beam radiation and brachytherapy implant affects rectal morbidity and likelihood of cure in the treatment of intermediate-risk prostate cancer...
  63. ncbi request reprint I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial
    Andrew Herstein
    Department of Radiation Oncology, Seattle, Washington, USA
    Cancer J 11:385-9. 2005
    ..We tested the hypothesis that the shorter half-life of Pd-103 versus I-125 results in different late radiation-related morbidities following prostate brachytherapy...
  64. ncbi request reprint 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial
    Kent Wallner
    Department of Veterans Affairs, Radiation Oncology, Puget Sound Health Care System, Seattle, WA 98108 1597, USA
    Radiother Oncol 75:307-10. 2005
    ..Similar to classic randomized Wilm's tumor studies from the 1980s, the intention of the trial design was to decrementally test the need for beam radiation...
  65. doi request reprint Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy
    L Christine Fang
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, Washington 98195, USA
    Urology 71:146-50. 2008
    ....
  66. ncbi request reprint Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer
    Tracy Sherertz
    Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, 1600 S Columbian Way, Seattle, WA 98108 1597, USA
    Brachytherapy 3:130-5. 2004
    ..To evaluate the contribution of various clinical and radiation treatment parameters to the likelihood of late rectal bleeding after brachytherapy plus supplemental beam radiation (EB)...
  67. ncbi request reprint Isolation and characterization of human and mouse WDR19,a novel WD-repeat protein exhibiting androgen-regulated expression in prostate epithelium
    Biaoyang Lin
    The Institute for Systems Biology, 1441 North 34th Street, Seattle, WA, 98103, USA
    Genomics 82:331-42. 2003
    ..WDR19 transcripts exhibit alternative splicing in which two isoforms appear to be prostate restricted, a property that could be exploited for designing diagnostic or therapeutic strategies for prostate carcinoma...
  68. pmc Human cancers express a mutator phenotype
    Jason H Bielas
    Department of Pathology, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 103:18238-42. 2006
    ....
  69. ncbi request reprint 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial
    Kent Wallner
    Department of Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA 98108, USA
    Int J Radiat Oncol Biol Phys 57:1297-303. 2003
    ..To compare prostate cancer control rates in patients who received (125)I vs. (103)Pd...
  70. ncbi request reprint Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy
    Daniel Reed
    Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington, USA
    Urology 62:683-8. 2003
    ..To make some preliminary observations regarding the biochemical characteristics of the doubly confusing picture of prostate-specific antigen (PSA) spikes and histologically positive biopsies after prostate brachytherapy...
  71. pmc A molecular correlate to the Gleason grading system for prostate adenocarcinoma
    Lawrence True
    Department of Pathology, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 103:10991-6. 2006
    ..Furthermore, in identifying a profile of 86 genes that distinguish high- from low-grade carcinomas, we have generated a set of potential targets for modulating the development and progression of the lethal prostate cancer phenotype...
  72. pmc Multicolor multicycle molecular profiling with quantum dots for single-cell analysis
    Pavel Zrazhevskiy
    Department of Bioengineering, University of Washington, Seattle, Washington, USA
    Nat Protoc 8:1852-69. 2013
    ..As a result, this protocol can be used by biomedical researchers for a variety of cell staining applications, and, with further optimization, for staining of other biological specimens (e.g., clinical tissue sections). ..
  73. ncbi request reprint Development of the Minimum Information Specification for In Situ Hybridization and Immunohistochemistry Experiments (MISFISHIE)
    Eric W Deutsch
    Institute for Systems Biology, Seattle, Washington 98103, USA
    OMICS 10:205-8. 2006
    ..The full specification will soon be published as a version 1.0 proposal to the community, upon which a more full discussion must take place so that the final specification may be achieved with the involvement of the whole community...
  74. pmc Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer
    Jennifer D Wu
    Department of Medicine, University of Washington, Seattle, WA, USA
    Transl Oncol 2:39-45. 2009
    ....
  75. ncbi request reprint I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial
    Kent Wallner
    Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, Washington 98108 1597, USA
    Cancer J 8:67-73. 2002
    ..The purpose of this study was to test the hypothesis that the shorter half-life of Pd-103 versus I-125 results in a shorter duration of radiation-related symptoms after prostate brachytherapy...
  76. ncbi request reprint Multifaceted genitourinary lymphoma
    M Reza Taheri
    Department of Radiology, University of Washington, Seattle, WA 98146, USA
    Curr Probl Diagn Radiol 37:80-93. 2008
    ..This article provides a pictorial review of the genitourinary lymphoma and the pertinent organ-specific clinical manifestations of this disease...
  77. pmc Characterization of prostate cell types by CD cell surface molecules
    Alvin Y Liu
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Am J Pathol 160:37-43. 2002
    ..The cell-type specificity of CD molecules increases the prospect of isolating specific cell populations, using such techniques as laser capture microdissection and flow cytometry, for cell-specific molecular studies...
  78. ncbi request reprint Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients
    Thomas D Schmittgen
    Division of Pharmaceutics, Ohio State University, College of Pharmacy, Columbus, OH 43210, USA
    Int J Cancer 107:323-9. 2003
    ..We note increased PSMA expression in some malignant tissues, however, these increases are modest in magnitude. We also report that the expression of a novel splice variant, PSM-D, is elevated in prostate cancer metastases...
  79. ncbi request reprint The role of tissue microarrays in prostate cancer biomarker discovery
    Milton W Datta
    Hospital Pathology Associates, Abbott Northwestern Hospital, University of Minnesota, Minneapolis, MN 55407, USA
    Adv Anat Pathol 14:408-18. 2007
    ..The processes used here can be applied to any tumor type to improve patient diagnosis, prognosis, and treatment response prediction...
  80. ncbi request reprint Prostate-specific antigen: a clinical and mathematical conundrum
    Kristin R Swanson
    Am J Clin Pathol 125:331-3. 2006
  81. ncbi request reprint A challenge for the diagnostic immunohistopathologist. Adding the CD phenotypes to our diagnostic toolbox
    Lawrence D True
    Am J Clin Pathol 120:13-5. 2003
  82. ncbi request reprint On the use of quantitative modeling to help understand prostate-specific antigen dynamics and other medical problems
    Kristin R Swanson
    Am J Clin Pathol 119:14-7. 2003
  83. ncbi request reprint Flow cytometry analysis of proliferative lesions at the gastrocystoplasty anastomosis
    Clare E Close
    Departments of Surgery and Pediatrics, University of Nevada School of Medicine, Las Vegas, NV, USA
    J Urol 169:365-8. 2003
    ..We used this technique to evaluate transitional cell metaplasia in rat gastrocystoplasty specimens...
  84. ncbi request reprint How wide is the spectrum of neuroendocrine carcinoma of the urinary bladder?
    Funda Vakar-Lopez
    Am J Clin Pathol 128:723-5. 2007